Immunis Recruits Individuals with Muscle Atrophy for Phase 1/2a Clinical Trial
Immunis Chairman Dr. Hans Keirstead to Present at Global Life Science Partnering and Investor Conference
The BIO CEO and Investor Conference is a premier four-day event where institutional investors, industry analysts and senior biotechnology executives shape the investment landscape of biotech. The abundant partnering opportunities, company presentations, and educational sessions collectively focus on therapeutic advancements, market outlook, and policy priorities. It is with pleasure that Dr. Keirstead will take part in such an exclusive speaker lineup amongst talented industry leaders.
About BIO CEO and Investor Conference
BIO CEO and Investor Conference, now in its 25th year, is one of the largest events for C-Suite leaders and the investor and banking communities. The meeting provides an incredible platform for networking amongst industry leaders for business growth and development. For more information please visit: www.bio.org/events/bio-ceo-investor-conference
About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
###